MiPLA (N-methyl-N-isopropyl lysergamide, also known as lysergic acid methylisopropylamide) is a synthetic psychedelic of the lysergamide family. It is structurally distinct from LSD in its amide substitution: where LSD carries a symmetric diethyl amide group, MiPLA features an asymmetric N-methyl-N-isopropyl amide — one methyl group and one isopropyl group on the amide nitrogen. This structural difference modifies the steric and electronic properties of the amide binding pocket interaction with 5-HT2A receptors. MiPLA acts as a direct compound in its own right and is the parent molecule for the prodrug 1cP-MiPLA.
Community experience with MiPLA describes a psychedelic experience that is notably shorter than LSD, typically 4–7 hours, with a character that users frequently describe as more mentally clear and less visually overwhelming than LSD. Some users describe the experience as having a more manageable quality — retaining cognitive clarity at doses that would be intensely overwhelming with LSD. This has made MiPLA of particular interest to users who value a shorter, cleaner lysergamide experience. Community reports from those microdosing note subtle but real effects at sub-perceptual doses, described as improving mood and focus.
MiPLA occupies a relatively obscure position in the broader lysergamide landscape, overshadowed by more widely documented compounds such as 1P-LSD and AL-LAD. However, its genuinely distinct character compared to LSD — rather than simply being an LSD equivalent — has attracted dedicated community interest among those exploring lysergamide diversity. The shorter duration and reportedly cleaner headspace make it relevant for specific use cases.
Testing with Ehrlich reagent is essential before use. Do not confuse with MiPT (N-methyl-N-isopropyl tryptamine), a tryptamine compound — despite name similarity, these are pharmacologically unrelated.
Safety at a Glance
High Risk- Ehrlich reagent: purple/violet reaction confirms an indole compound. Do not confuse MiPLA with MiPT — these are struc...
- Community reports suggest MiPLA may be slightly less potent than LSD on a per-microgram basis:
- Toxicity: Acute Toxicity No formal toxicological data exist for MiPLA in humans. By structural and pharmacological analogy to L...
- Overdose risk: Overdose The LD50 of MiPLA is unknown. Adverse psychological reactions may be more likely to occu...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4 hrs – 6 hrsHow It Feels
You might not notice it has begun. MiPLA does not announce itself with visual fireworks or cognitive upheaval. Instead, around thirty minutes after ingestion, you become aware of a very gentle shift in how you are inhabiting your body. There is a mild warmth, a slight loosening of muscular tension, and a quality of presence that is hard to name but easy to feel. The world has not changed; your relationship to it has adjusted by a few barely perceptible degrees.
The most notable effect is on music. Put on headphones and within minutes the change becomes unmistakable. Instruments separate and breathe. Bass frequencies gain physical presence, resonating in the chest cavity. Melodies carry an emotional weight that seems disproportionate to the apparent mildness of the substance. Details that normally sit below the threshold of attention, the brush of a drummer's fingers on a cymbal, the room ambience captured in a recording, the micro-timing variations in a vocalist's phrasing, rise to the surface and become vivid. This auditory enhancement is MiPLA's signature gift, and for many it is sufficient reason for the experience.
Visually, almost nothing happens. At higher doses there may be a marginal increase in color saturation and a faint, barely perceptible wavering at the edges of complex patterns, but these effects are so subtle they could be attributed to expectation alone. Cognitively, the experience is characterized by a mild increase in associative thinking and a gentle mood elevation. There is no psychedelic confusion, no ego dissolution, no conceptual restructuring. You remain entirely yourself, simply with slightly enhanced sensory appreciation and a quietly elevated mood.
The experience fades so gradually that identifying an endpoint is largely a matter of retrospective judgment. After four to five hours the music enhancement has softened, the warmth has dissipated, and ordinary consciousness has resumed without fanfare. There is no comedown, no depletion, no residual stimulation. MiPLA is perhaps the most utilitarian of the lysergamides, a subtle tool for sensory enhancement that asks very little of the user and delivers a modest, well-defined reward.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(21)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Changes in felt bodily form— Changes in felt bodily form is the experience of one's body feeling as though it has altered its phy...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Increased salivation— Increased salivation (hypersalivation or sialorrhea) is the excessive production of saliva beyond wh...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(17)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(19)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Music appreciation enhancement— A profound enhancement of one's enjoyment and emotional connection to music, making songs feel deepl...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(2)
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
MiPLA acts as a direct partial agonist at serotonin 5-HT2A receptors, not as a prodrug. The asymmetric N-methyl-N-isopropyl amide substitution produces a different steric profile at the amide binding region of 5-HT2A receptors compared to LSD's symmetric diethyl amide. This structural difference appears to produce faster receptor dissociation kinetics and/or different signaling bias, likely accounting for the shorter duration and different qualitative character reported by community members. As with all lysergamides, 5-HT2A partial agonism in cortical pyramidal neurons is the primary driver of psychedelic effects.
Receptor Targets
- 5-HT2A receptors — primary psychedelic target; partial agonist; asymmetric amide substitution modifies binding geometry relative to LSD
- 5-HT1A receptors — likely partial agonist; may contribute to clearer, less overwhelming character
- 5-HT2C receptors — expected affinity
- Dopamine D2/D3 receptors — moderate affinity based on structural analogy; contributes to mood and stimulation
- α-adrenergic receptors — sympathomimetic effects
Pharmacokinetics
No formal human pharmacokinetic data exist for MiPLA. Community-reported onset at 30–60 minutes and duration of 4–7 hours suggest faster receptor kinetics or more rapid metabolism compared to LSD. The asymmetric amide structure may be more susceptible to metabolic cleavage than LSD's symmetric diethyl group. No prodrug conversion step; MiPLA acts directly.
Tolerance
Cross-tolerance with LSD and all serotonergic psychedelics. Functional tolerance within 24–48 hours, reversal over 5–7 days.
Detection Methods
Urine Detection
MiPLA and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.
Blood and Serum Detection
Blood detection windows for MiPLA are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.
Standard Drug Panel Inclusion
MiPLA is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.
Confirmatory Methods
When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Ehrlich reagent is the primary tool for MiPLA. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins
MiPLA was synthesized as part of the systematic lysergamide structure-activity research conducted at Sandoz Laboratories in the mid-20th century. Albert Hofmann and colleagues explored numerous amide substitutions on the lysergic acid core, including asymmetric amide structures. MiPLA was characterized as an active lysergamide but was not developed as a pharmaceutical compound.
Research Chemical Market
MiPLA gained attention in the research chemical community, particularly after Alexander Shulgin and Ann Shulgin's TiHKAL (1997) catalogued related lysergamide derivatives. It attracted specific interest from users seeking shorter-duration or cleaner-character alternatives to LSD. Its role as the parent compound of 1cP-MiPLA further embedded it in the research chemical knowledge base.
Legal Status
MiPLA is not specifically scheduled under international drug conventions. It may fall under analog act provisions in the United States and novel psychoactive substance laws in the UK and EU. The UK's Psychoactive Substances Act 2016 covers MiPLA along with all other psychoactive compounds. Legal status should be verified locally before obtaining or possessing this compound.
Harm Reduction
Testing
Ehrlich reagent: purple/violet reaction confirms an indole compound. Do not confuse MiPLA with MiPT — these are structurally unrelated despite name similarity. Confirm compound identity before use.
Dosing
Community reports suggest MiPLA may be slightly less potent than LSD on a per-microgram basis:
- Threshold: 50–75 μg
- Light: 75–125 μg
- Common: 125–250 μg
- Strong: 250–400 μg
The shorter duration (4–7 hours) may tempt premature redosing — avoid this, as peak effects take 1–2 hours to develop and additional doses can compound unexpectedly.
Set and Setting
- Stable mental state; familiar, comfortable environment
- The reportedly clearer, shorter experience may make MiPLA more suitable for structured or daytime use than LSD, but standard precautions still apply
- Trip sitter recommended, especially for first experiences
Dangerous Combinations
- Lithium — Contraindicated; seizure and cardiac events documented with lysergamides
- MAOIs — Serotonin syndrome risk
- Tramadol — Seizure risk
- Cannabis — Risk of amplified anxiety
- Stimulants — Cardiovascular and psychological intensity amplification
Emergency Protocol
- Difficult experience: environment change, grounding techniques
- Benzodiazepines (diazepam 10–20 mg) for acute distress
- Emergency services for any physical safety concern
Toxicity & Safety
Acute Toxicity
No formal toxicological data exist for MiPLA in humans. By structural and pharmacological analogy to LSD, acute pharmacological toxicity is expected to be very low. No fatalities directly attributable to MiPLA have been reported.
Cardiovascular Effects
Sympathomimetic effects consistent with the lysergamide class: mild tachycardia, blood pressure elevation, mydriasis. Contraindicated with cardiovascular disease.
Psychological Risks
- Acute anxiety and panic — dose-dependent; may be less intense than LSD at comparable effect levels per community reports, but dose escalation still carries risk
- Psychosis induction — absolute contraindication with history of schizophrenia or bipolar I disorder
- HPPD — risk with any serotonergic psychedelic
Contraindications
Personal or family history of psychosis or bipolar disorder; lithium, MAOI, antipsychotic, or tramadol use; cardiovascular disease.
Overdose
No documented pharmacological overdoses. Benzodiazepines for acute psychological distress.
Addiction Potential
low potential for abuse and dependence
Overdose Information
Overdose
The LD50 of MiPLA is unknown. Adverse psychological reactions may be more likely to occur at higher doses. Some of these include anxiety, delusions, panic attacks and (more rarely) seizures. Medical attention is usually only needed in the case of severe psychotic episodes or “fake acid” (a counterfeit substance such as 25x-NBOMe or DOx). Administration of benzodiazepines or antipsychotics can help to relieve the negative psychological effects of MiPLA.
Like other serotonergic psychedelics,low potential for abuse and dependence. This is owing to its structural and pharmacological similarities with LSD. See this section to learn more about the dependence and abuse potential of LSD. It should be noted that all claims related to the abuse potential of MiPLA are preliminary and based on anecdotal (as opposed to clinical) evidence and should be interpreted with caution.
As with LSD,almost immediately after ingestion. After that,5-714 days to be return to baseline (in the absence of further consumption).
Due to its activity at the 5-HT2A receptor, MiPLA produces cross-tolerance with Cross-all psychedelics, meaning that after the consumption of MiPLA all psychedelics will have a reduced effect.
MiPLA is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area throughout most of the world, meaning that it might not be specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
- Austria: MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanz
Tolerance
| Full | almost immediately after ingestion |
| Half | 5-7 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
MiPLA is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area throughout most of the world, meaning that it might not be specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
Austria: MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Germany: MiPLA is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland: MiPLA can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.
United States: MiPLA is not scheduled but may be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.
Responsible use
Research chemical
Psychedelics
LSD
MiPLA (Wikipedia)
MiPLA (TiHKAL / Isomer Design)
Discussion
The Small & Handy MiPLA Thread (Bluelight)
Halberstadt, A. L., Klein, L. M., Chatha, M., Valenzuela, L. B., Stratford, A., Wallach, J., ... & Brandt, S. D. (2018). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology, 1-10. http://dx.doi.org/10.1007/s00213-018-5055-9
Nichols, D. E. (2001). LSD and its lysergamide cousins. The Heffter Review of Psychedelic Research. Santa Fe, New Mexico: Heffter Research Institute, 80-87.
Experience Reports (1)
Tips (4)
Clear your schedule for the full duration of MiPLA plus afterglow. Do not plan any obligations, driving, or important decisions for the day. Having a time pressure or commitment hanging over you adds unnecessary anxiety.
Psychedelic tolerance builds rapidly. Wait at least 1-2 weeks between uses of MiPLA for full tolerance reset. Taking the same dose the next day would require roughly double the amount for comparable effects.
Start with a low dose of MiPLA if it is your first time. You can always take more next time but you cannot take less once ingested. The difference between a comfortable and an overwhelming experience can be surprisingly small.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid MiPLA and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
See Also
Same Class
References (5)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- PubChem: MiPLA
PubChem compound page for MiPLA (CID: 102060927)
pubchem - MiPLA - TripSit Factsheet
TripSit factsheet for MiPLA
tripsit - MiPLA - Wikipedia
Wikipedia article on MiPLA
wikipedia